A drug discovery platform to identify compounds that inhibit EGFR triple mutants is a research paper published in Nature Chemical Biology (2020). On theSindex it has a DataRank of 1.4. It has been cited 38 times, with 22 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.550
From this paper's citation signal
Citation Network Contribution
0.835
From 20 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 22 citers.
Canadian Cancer Society Research Institute
Grant: 703889
Cancer Research Society
Grant: 23235
NIGMS NIH HHS
Grant: R35 GM122485
NCI NIH HHS
Grant: R01 CA079992
NCI NIH HHS
Grant: R01 CA198164
National Institutes of Health
Grant: 5R35GM122485-02
Understanding Signaling by Non-Canonical Receptor Tyrosine Kinases
National Institutes of Health
Grant: 5R01CA198164-10
Understanding EGF receptor activation by growth factors and oncogenic mutations
Consortium Québécois sur la Découverte du Médicament (CQDM) (Explore) and OCE (#23929) Genome Canada via Ontario Genomics
MeSH Terms
Keywords
Sustainable Development Goals